Eesti - eesti - Ravimiamet

krka, d.d., novo mesto - tramadool+paratsetamool - õhukese polümeerikattega tablett - 75mg+650mg 80tk; 75mg+650mg 90tk; 75mg+650mg 30tk; 75mg+650mg 40tk; 75mg+650mg 20tk

Eesti - eesti - Ravimiamet

krka, d.d., novo mesto - tramadool+paratsetamool - õhukese polümeerikattega tablett - 37,5mg+325mg 70tk; 37,5mg+325mg 80tk; 37,5mg+325mg 40tk; 37,5mg+325mg 30tk; 37,5mg+325mg 50tk; 37,5mg+325mg 10tk; 37,5mg+325mg 60tk; 37,5mg+325mg 100tk

Eesti - eesti - Ravimiamet

accord healthcare b.v. - paratsetamool - tablett - 500mg 56tk; 500mg 50tk; 500mg 10tk; 500mg 32tk; 500mg 100tk; 500mg 30tk; 500mg 20tk; 500mg 16tk; 500mg 300tk; 500mg 12tk; 500mg 8tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - immunosupressandid - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Euroopa Liit - eesti - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuuria, paroksüsmaalne - selektiivsed immunosupressandid - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Eesti - eesti - Ravimiamet

stada arzneimittel ag - atsetüültsüsteiin - kihisev tablett - 200mg 20tk; 200mg 10tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - atsetüültsüsteiin - suukaudne pulber kotikeses - 600mg 60tk; 600mg 8tk; 600mg 20tk; 600mg 30tk; 600mg 10tk; 600mg 14tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - atsetüültsüsteiin - suukaudse lahuse pulber - 600mg 30tk; 600mg 60tk; 600mg 20tk; 600mg 90tk; 600mg 10tk; 600mg 6tk

Eesti - eesti - Ravimiamet

pharmaestica manufacturing oÜ - atsetüültsüsteiin - kihisev tablett - 600mg 10tk; 600mg 12tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - atsetüültsüsteiin - süstelahus - 100mg 1ml 3ml 5tk